Long-bond plunge on 'buybacks'… Moderna shares soar 170%

According to the FOMC minutes for July, released publicly, many participants agreed that additional tightening would be needed if the slowdown in inflation proved insufficient. Although the benchmark rate was held steady at the time, three members strongly called for a 0.25-percentage-point hike, and the hawkish stance within the Fed remains clearly visible.

As inflation and employment data in U.S. economic indicators show a complex picture, market attention on the Fed's monetary policy decisions continues.

At this meeting, a plan to reduce the number of regularly scheduled FOMC meetings was newly discussed. A proposal was raised to cut the current eight meetings per year to six, holding them roughly once every two months.

The proposal is reportedly aimed at giving more time between meetings to gather data and strengthen medium- to long-term policy analysis.

It will raise the per-operation purchase limit from the previous $2 billion to at least $4 billion and begin full-scale implementation from next month.

This is seen as a response to the recent surge in corporate bond issuance for AI investment and concerns over government fiscal deficits.

He especially stressed that strong economic growth does not necessarily lead directly to inflation, so current high interest rates should come down, raising his voice on the point.

He emphasized the performance of digital assets and demanded swift passage of the Clarity Act to clarify related regulations.

This is the first time a personalized mRNA therapy has demonstrated clear therapeutic efficacy in the final stage of clinical trials.

Following this news, Moderna's shares more than doubled in a single day, and the combined market capitalization of the two companies rose by $50 billion.

Sarah Friar, OpenAI's chief financial officer, told an all-hands meeting that the listing could be brought forward if its earnings recovery continues, but officially projected that the company would be publicly listed around 2027. This means the push to go public within this year has fallen through.

Friar explained that an IPO is not a finish line but a milestone for raising capital, and laid out a strategy to pursue the listing after proving the company's value.

This wariness shows that expectations for the rapid growth of the AI industry coexist with concerns about overvaluation.

As part of the deal, Google secured warrants to purchase 59 million Marvell Technology shares.

The partnership is viewed as a large-scale collaboration that could generate up to $120 billion in revenue through 2033.

Although the news of large-scale fundraising came out, concerns over share dilution came to the fore, and the analysis is that selling pressure from investors grew.

This successful trial is expected to be an important milestone that raises the commercialization potential of personalized mRNA cancer therapies.

Merck's strategy to extend the product life of Keytruda and secure new growth drivers ahead of its patent expiry appears to have received a positive reception.

This is a significant improvement over the previous quarter.

Sales in skincare and fragrance were solid, and sales in the Chinese market also exceeded expectations, contributing to the earnings improvement.

The planned acquisition is about 24 million common shares, which it will buy on the open market through November 19 and then cancel in full.

The company also expanded its free cash flow return ratio to 50% or more and expressed its intention to implement its existing shareholder return policy early.

1 cathode material company, covering the entire secondary battery materials chain, from supplying lithium ore and brine lithium to recycling spent batteries.

Through this agreement, the company plans to stabilize its lithium hydroxide supply chain, strengthen the battery materials value chain, and secure global competitiveness.

April Bio's shares plunged more than 15% in aftermarket trading amid concerns that development of its licensed drug candidate would be halted. This followed the release of clinical results by its partner, Lundbeck.

In response, the company said the drug's safety and mechanism of action have been confirmed, so it will continue development by changing the indication to a different disease, expressing its commitment to normalizing development.